Shirin Khambata‐Ford

机构：Daiichi Sankyo (United States)

发表论文 55 篇 · 总被引 7325 次 · h-index 19

代表论文

• Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study (2019 · Lung Cancer · 被引 162)
• Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms (2017 · PLoS ONE · 被引 100)
• Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer (2013 · British Journal of Cancer · 被引 94)
• Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients (2018 · Cancer Cytopathology · 被引 89)
• Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer (2012 · Clinical Cancer Research · 被引 35)
• Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the KRAS Gene in Patients with Metastatic Colorectal Cancer: Analysis of the NCIC CTG CO.17 Trial (2012 · Archives of Pathology & Laboratory Medicine · 被引 31)